Recognition of the insulin resistance syndrome is clinically important as it predicts both type 2 diabetes and cardiovascular disease. NCEP and WHO have recently published formal definitions that may help identification of the syndrome. Given the large variation of the prevalence and features of the insulin resistance syndrome, the definitions are oversimplifications as they attempt to define a biological continuous phenomenon by fixed numbers, which are unlikely to be equally useful in risk prediction in different ethnic groups. Clinical judgement therefore remains essential in assessing individuals at risk. Such risk assessment obviously also include cardiovascular risk factors such as gender, ethnicity, low‐density lipoprotein cholesterol, smoking, and family history of cardiovascular disease.